Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen

Coya Therapeutics (NASDAQ:COYA) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other equities research analysts have also recently weighed in on COYA. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Monday, February 2nd. D. Boral Capital reissued a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Monday, March 16th. Chardan Capital restated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Monday, March 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Stock Performance

Coya Therapeutics stock opened at $4.21 on Friday. The company has a 50-day simple moving average of $4.69 and a 200-day simple moving average of $5.53. The firm has a market capitalization of $98.77 million, a P/E ratio of -3.31 and a beta of 0.23. Coya Therapeutics has a one year low of $3.94 and a one year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.26). The firm had revenue of $3.96 million during the quarter, compared to the consensus estimate of $1.93 million. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. As a group, sell-side analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new stake in shares of Coya Therapeutics during the third quarter worth $28,000. CIBC Private Wealth Group LLC acquired a new stake in Coya Therapeutics during the 4th quarter worth about $47,000. Occudo Quantitative Strategies LP purchased a new stake in Coya Therapeutics during the fourth quarter valued at about $66,000. Lantern Wealth Advisors LLC acquired a new position in shares of Coya Therapeutics in the third quarter worth about $66,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Coya Therapeutics in the fourth quarter worth approximately $81,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.